Jodid (Tablets) Instructions for Use

Instructions
Dosage forms

ATC Code

H03CA (Iodine preparations)

Active Substance

Potassium iodide (Ph.Eur. European Pharmacopoeia)

Clinical-Pharmacological Group

Iodine preparation for the prevention and treatment of thyroid diseases

Pharmacotherapeutic Group

Thyroxine synthesis regulator – iodine preparation

Pharmacological Action

A product containing inorganic iodine. When iodides enter the cells of the follicular epithelium of the thyroid gland, under the influence of the enzyme iodide peroxidase, iodine is oxidized to form elemental iodine, which is incorporated into the tyrosine molecule. In this process, one part of the tyrosine radicals in thyroglobulin is iodinated. The iodinated tyrosine radicals condense into thyronines, the main ones being thyroxine (T₄) and triiodothyronine (T₃). The resulting complex of thyronine and thyroglobulin is secreted as a stored form of the thyroid hormone into the follicular colloid and remains in this state for several days or weeks. In case of iodine deficiency, this process is disrupted.

Potassium iodide, compensating for the iodine deficiency, helps restore the impaired synthesis of thyroid hormones.

With a normal iodine content in the environment, under the influence of excess iodides, the biosynthesis of thyroid hormones is inhibited, their release from thyroglobulin is reduced, the sensitivity of the thyroid gland to the pituitary thyroid-stimulating hormone is decreased, and its secretion by the pituitary gland is blocked.

Pharmacokinetics

When taken orally, it is rapidly absorbed from the gastrointestinal tract. It is widely distributed in all tissues and body fluids.

Indications

Prevention and treatment of endemic goiter. Prevention of goiter recurrence during complex treatment with thyroid hormone preparations.

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
E01.0	Diffuse (endemic) goiter associated with iodine deficiency
E01.1	Multinodular (endemic) goiter associated with iodine deficiency
E01.2	Iodine-deficiency-related (endemic) goiter, unspecified

ICD-11 code	Indication
5A00.10	Diffuse goiter associated with iodine deficiency
5A00.11	Multinodular goiter associated with iodine deficiency
5A00.1Z	Iodine-deficiency-related thyroid disorders and allied conditions, unspecified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Determine the dosage regimen individually based on the patient’s age and clinical indication.

For prophylaxis of endemic goiter, administer a daily dose of 50-100 mcg of iodine to children.

Administer a daily dose of 100-200 mcg of iodine to adolescents and adults for prophylaxis.

For treatment of endemic goiter, use higher doses as clinically indicated; adjust based on thyroid function tests.

To prevent goiter recurrence during combination therapy with thyroid hormones, use the standard prophylactic adult dose.

Adjust the dose for elderly patients with caution; monitor for signs of hyperthyroidism.

Do not exceed the maximum daily dose without medical supervision due to the risk of iodine-induced thyroid dysfunction.

For long-term therapy, perform regular monitoring of thyroid hormonal status and clinical response.

Discontinue treatment and investigate if symptoms of iodism or other adverse reactions occur.

Adverse Reactions

Manifestations of iodism: swelling of the nasal mucosa, urticaria, angioedema, eosinophilia, shock, tachycardia, irritability, sleep disorders, increased sweating, diarrhea (in patients over 40 years of age); in some cases, when used in doses exceeding 300-1000 mcg/day, the development of hyperthyroidism is possible (especially in elderly patients, in the presence of nodular or diffuse toxic goiter); with high-dose therapy (more than 1 mg/day), iodine-induced goiter and, accordingly, hypothyroidism may develop.

Contraindications

Hypersensitivity to iodine preparations; marked hyperthyroidism, latent hyperthyroidism (when used in doses exceeding 150 mcg/day), toxic adenoma, nodular or diffuse toxic goiter (when used in doses of 300-1000 mcg/day), dermatitis herpetiformis (Duhring’s disease), pregnancy and breastfeeding (when used in doses of 1-2 mg/day).

Use in Pregnancy and Lactation

During pregnancy, use is possible only in recommended doses, because iodine crosses the placental barrier and can cause the development of hypothyroidism and goiter in the fetus.

Iodine is excreted in breast milk. When used by the mother during lactation (breastfeeding) in doses of more than 1 mg/day, there is a risk of developing hypothyroidism in the infant.

Use in Renal Impairment

During therapy in patients with renal impairment, hyperkalemia may develop.

Pediatric Use

Can be used in children according to indications in age-appropriate recommended doses and dosage forms.

Geriatric Use

Should be used with caution in elderly patients due to the risk of developing hyperthyroidism in this category of patients.

Special Precautions

During therapy in patients with renal impairment, hyperkalemia may develop.

Drug Interactions

With simultaneous high-dose therapy with iodine and potassium-sparing diuretics, hyperkalemia may develop; with lithium preparations – the development of goiter and hypothyroidism. Perchlorate and thiocyanate competitively inhibit the uptake of iodine by the thyroid gland, while TSH stimulates it.

Antithyroid drugs weaken the effect (mutually).

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer